Literature DB >> 19344122

Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.

Eirini A Fragogeorgi1, Christos Zikos, Eleni Gourni, Penelope Bouziotis, Maria Paravatou-Petsotas, George Loudos, Nikolaos Mitsokapas, Stavros Xanthopoulos, Mary Mavri-Vavayanni, Evangelia Livaniou, Alexandra D Varvarigou, Spyridon C Archimandritis.   

Abstract

It has been shown that gastrin releasing peptide receptors (GRPRs) are overexpressed in various types of cancer cells. Bombesin is an analogue of the mammalian GRP that binds with high specificity and affinity to GRPRs. Significant research efforts have been lately devoted to the design of radiolabeled 8 or 14 aminoacid bombesin (BN) peptides for the detection (either with gamma or positron emitting radionuclides) and therapy (with beta(-) emitting radionuclides) of cancer. The specific aim of the present study was to further investigate the radiolabeled peptide structure and to determine whether the total absence of a linker or the use of a basic diverse amino acid linker could influence the biodistribution profile of the new compounds for specific targeting of human prostate cancer. Thus, two new derivatives with the structure Gly-Gly-Cys-X-BN[2-14], where linker X is either zero (I) or Orn-Orn-Orn (Orn: ornithine) (II) were designed and synthesized. The corresponding (99m)Tc-BN derivatives were obtained with high radiochemical yield (>98%) and had almost identical retention times in RP-HPLC with the (185/187)Re complexes, which were also characterized by ESI-MS. Metabolic stability was found to be high in human plasma, moderate in PC-3 cells, and rather low in mouse liver and kidney homogenates for both BN derivatives studied. The BN derivative without the spacer was less stable in cell culture and liver homogenates. A satisfactory binding affinity to GRPRs, in the nanomolar range, was obtained for both BN derivatives as well as for their Re complexes, with BN (II) demonstrating the highest one. In vitro internalization/externalization assays indicated that approximately 6% of BN (I) and approximately 25% of BN (II) were internalized into PC-3 cells. In vivo evaluation in normal Swiss mice and in tumor bearing SCID mice showed that BN (II) presented higher tumor and pancreas uptake than BN (I). Small animal SPECT dynamic imaging, carried out after an injection of BN (II) in mice bearing PC-3 tumors, resulted in PC-3 tumor delineation with low background activity. Overall, this study performed for two new N(3)S-X-BN[2-14] derivatives indicated that hydrophilicity and charge strongly affected the in vitro and in vivo binding properties and the biodistribution pattern. This finding is confirmed by SPECT imaging of BN (II), which is under further in vivo evaluation for detecting cancer-positive GRPRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344122     DOI: 10.1021/bc800475k

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.

Authors:  Irene Tsiapa; George Loudos; Eirini A Fragogeorgi; Penelope Bouziotis; Dimitrios Psimadas; Stavros Xanthopoulos; Maria Paravatou-Petsotas; Lazaros Palamaris; Alexandra D Varvarigou; Dimitris Karnabatidis; George C Kagadis
Journal:  Cancer Biother Radiopharm       Date:  2014-12       Impact factor: 3.099

3.  Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma.

Authors:  Haixun Guo; Yubin Miao
Journal:  J Nucl Med       Date:  2014-11-07       Impact factor: 10.057

4.  Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

5.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.

Authors:  Molly E Martin; M Sue O'Dorisio; Whitney M Leverich; Kyle C Kloepping; Susan A Walsh; Michael K Schultz
Journal:  Recent Results Cancer Res       Date:  2013

6.  Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFRβ) Imaging: Influence of Different Linkers.

Authors:  Nurmaya Effendi; Kenji Mishiro; Kazuhiro Shiba; Seigo Kinuya; Kazuma Ogawa
Journal:  Molecules       Date:  2020-12-23       Impact factor: 4.411

7.  MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.

Authors:  Miguel Ángel Morcillo; Ángel García de Lucas; Marta Oteo; Eduardo Romero; Natalia Magro; Marta Ibáñez; Alfonso Martínez; Guillermo Garaulet; Alicia G Arroyo; Pedro Pablo López-Casas; Manuel Hidalgo; Francisca Mulero; Jorge Martínez-Torrecuadrada
Journal:  Contrast Media Mol Imaging       Date:  2018-08-26       Impact factor: 3.161

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.